Prof Carani B Sanjeevi, Department of Medicine, Karolinska Institutet, Solna, Sweden, and Senior Advisor, Business Sweden-Invest, Stockholm, Sweden
He earlier served as KI's scientific coordinator for India from 2000-12. He joined KI in 1989, which selects and awards Nobel Prize for Medicine & Physiology. His area of research interest is in diabetes.
Dr Sanjeevi is also the senior advisor for life science at Business Sweden in Stockholm, and as well as an advisor to TATA Capital Healthcare Fund in India, HBM Healthcare Fund, Switzerland.
He also is a member of the scientific advisory board of Seraxis (USA) Chellaram Diabetes Institute (Pune) and 3Netra (Bangalore).
He serves in the editorial board of several scientific journals, and has edited ‘Immunology of Diabetes' series (of 5 volumes) for Annals of the New York Academy of Sciences, USA.
Q: Any advice for Indian life sciences companies seeking to establish or collaborate in Sweden?